[Skip to Content]
[Skip to Content Landing]

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Approximately 80% of hospitalized patients with COVID-19 report persistent symptoms several months after infection onset.1,2 However, knowledge of long-term outcomes among individuals with mild COVID-19 is scarce, and prevalence data are hampered by selection bias and suboptimal control groups.3,4 This cohort study investigated COVID-19–related long-term symptoms in health care professionals.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Charlotte Thålin, MD, PhD, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 18288 Stockholm, Sweden (charlotte.thalin@sll.se).

Accepted for Publication: March 26, 2021.

Published Online: April 7, 2021. doi:10.1001/jama.2021.5612

Author Contributions: Dr Thålin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Havervall, Phillipson, Mangsbo, Nilsson, Hober, Thålin.

Acquisition, analysis, or interpretation of data: Havervall, Rosell, Mangsbo, Nilsson, Hober, Thålin.

Drafting of the manuscript: Havervall, Nilsson, Thålin.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Havervall, Rosell, Nilsson.

Obtained funding: Nilsson, Hober, Thålin.

Administrative, technical, or material support: Havervall, Rosell, Nilsson, Hober.

Supervision: Phillipson, Mangsbo, Nilsson, Hober, Thålin.

Conflict of Interest Disclosures: Dr Mangsbo reported being a chief innovation officer for Ultimovacs and being a founder and board member for Immuneed and Strike Pharmaceuticals outside the submitted work. No other disclosures were reported.

Funding/Support: This research was funded by grants from the Knut and Alice Wallenberg Foundation, Jonas and Kristina af Jochnick Foundation, Leif Lundblad Family Foundation, Region Stockholm, and Erling Persson Family Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Carfì  A , Bernabei  R , Landi  F ; Gemelli Against COVID-19 Post-Acute Care Study Group.  Persistent symptoms in patients after acute COVID-19.   JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603PubMedGoogle ScholarCrossref
2.
Arnold  DT , Hamilton  FW , Milne  A ,  et al.  Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort.   Thorax. Published online December 3, 2020. doi:10.1136/thoraxjnl-2020-216086PubMedGoogle Scholar
3.
Logue  JK , Franko  NM , McCulloch  DJ ,  et al.  Sequelae in adults at 6 months after COVID-19 infection.   JAMA Netw Open. 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830PubMedGoogle Scholar
4.
Sudre  CH , Murray  B , Varsavsky  T ,  et al.  Attributes and predictors of long COVID.   Nat Med. Published online March 10, 2021. doi:10.1038/s41591-021-01292-yPubMedGoogle Scholar
5.
Rudberg  AS , Havervall  S , Månberg  A ,  et al.  SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.   Nat Commun. 2020;11(1):5064. doi:10.1038/s41467-020-18848-0PubMedGoogle ScholarCrossref
6.
Sheehan  KH , Sheehan  DV .  Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.   Int Clin Psychopharmacol. 2008;23(2):70-83. doi:10.1097/YIC.0b013e3282f2b4d6PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close